Kintara SVP Business Development John Liatos departs; separation terms include $226,667 severance

TuHURA Biosciences, Inc./NV

John Liatos stepped down as SVP Business Development effective Oct 25, 2021 to pursue other opportunities.
Separation agreement: 8 months base salary ($226,667), COBRA reimbursement for up to 8 months.
Stock options: additional 6 months vesting credit; vested options exercisable for 12 months post-termination.
Non-compete and non-solicitation provisions apply for 12 months following termination.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Liatos

Senior Vice President, Business Development

HURA · TuHURA Biosciences, Inc./NV

Effective: 2021-10-25
Filed: October 29, 2021, 7:59 PM ET

On October 25, 2021, Kintara Therapeutics, Inc. (the “Company”) and John Liatos, the Company’s Senior Vice President, Business Development, mutually agreed that Mr. Liatos would step down from his role as Senior Vice President, Business Development effective immediately to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Liatos resigned as Senior Vice President, Business Development at TuHURA Biosciences, Inc./NV.

Action: resigned
Role: Senior Vice President, Business Development

Exact text from the filing

On October 25, 2021, Kintara Therapeutics, Inc. (the “Company”) and John Liatos, the Company’s Senior Vice President, Business Development, mutually agreed that Mr. Liatos would step down from his role as Senior Vice President, Business Development effective immediately to pursue other opportunities.

View on SEC.gov

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0001564590-21-052943

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.